Any bid would compete against a $13.25-per-share proposal made by R1’s largest investor, New Mountain Capital, according to the report.
New Mountain and TCP-ASC — an investment vehicle jointly owned by TowerBrook and Ascension Health Alliance — previously discussed a joint proposal to take R1 private but were unable to come to an agreement, according to the report. New Mountain, which has a 32% interest in the company, decided to go solo on its offer.
Deliberations between TowerBrook and CD&R are ongoing and there is no certainty they will proceed with a bid, sources who asked not to be identified discussing confidential information told Bloomberg.
TowerBrook is R1’s second-largest shareholder with about a 30% stake in the company, according to the report.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
